Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rezera
Boston, Massachusetts, United Statesrezera.com ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Other
01
Overview
Rezera (formerly NodThera) is a clinical-stage biotechnology company focused on developing a portfolio of internally-invented, wholly-owned oral small-molecule inhibitors of the NLRP3 inflammasome. The company's therapeutic pipeline targets chronic inflammatory drivers of cardiovascular, metabolic, and neurologic diseases. Its lead candidate, ruvonoflast (formerly NT-0796), is a brain-penetrant NLRP3 inhibitor that recently completed Phase II trials (RESOLVE-1 and RESOLVE-2) and is slated to enter a registrational Phase III study for peripheral artery disease (PAD) in the first half of 2027. Rezera is also advancing trabzanoflast (formerly NT-0150), a brain-penetrant NLRP3 inhibitor optimized for neuroinflammatory indications like Parkinson's disease, with Phase I results expected in late 2026.
- Therapeutic areas
- CardiovascularNeurologyEndocrinology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Rezera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rezera.